Pharmacological Treatment of Ankylosing Spondylitis
Authors:
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 65 (15) , 2111-2127
Abstract
The purpose of this study was to review the evidence regarding the efficacy and safety of pharmacological therapies currently available for the treatment of ankylosing spondylitis (AS). A literature search using MEDLINE from 1966 through to April 2005 and a hand search of abstracts from the American College of Rheumatology (ACR) meetings for 2001 through to 2004 were performed. References of articles retrieved were also searched. The MEDLINE search yielded 570 citations and 157 abstracts from ACR were identified. Eighty-four studies were randomised controlled trials (RCTs); 53 fulfilled the inclusion criteria (pharmacological treatment of AS and RCT) and were included in this review. Statistical pooling of data was not performed because of the disparate outcome measures used. Eight RCTs found nonselective NSAIDs and two RCTs found cyclo-oxygenase (COX)-2-selective NSAIDs to be superior to placebo for relief of pain and improvement in physical function. Twenty-nine RCTs showed comparable efficacy and safety between nonselective NSAIDs. One RCT showed no difference between methylprednisolone 1g and 375mg. Seven RCTs assessing the efficacy of sulfasalazine (sulphasalazine) and two RCTs of methotrexate provided contradictory evidence as to their benefit for treatment of AS. One RCT showed intravenous pamidronate 60mg to be more effective than 10mg intravenously for the treatment of axial pain. All six RCTs of anti-tumour necrosis factor (TNF)-α agents demonstrated superiority to placebo for the treatment of axial and peripheral symptoms. Nonselective as well as COX-2-selective NSAIDs can be used for pain control in patients with AS. Other proven treatment options include sulfasalazine for the treatment of peripheral joint symptoms, while limited evidence supports the use of pamidronate or methotrexate, which require further studies. Anti-TNFα agents have been found very effective for the treatment of both peripheral and axial symptoms in patients with AS, but their use is limited by cost and uncertainty over long-term efficacy and safety.Keywords
This publication has 90 references indexed in Scilit:
- Six‐month results of a double‐blind, placebo‐controlled trial of etanercept treatment in patients with active ankylosing spondylitisArthritis & Rheumatism, 2003
- Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy.1999
- A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.1994
- Systematic Reviews: Identifying relevant studies for systematic reviewsBMJ, 1994
- Efficacy of Diclofenac/Misoprostol vs Diclofenac in the Treatment of Ankylosing SpondylitisDrugs, 1993
- Isoxicam vs ketoprofen in ankylosing spondylitis.British Journal of Clinical Pharmacology, 1986
- Flurbiprofen in the treatment of ankylosing spondylitis: A comparison with indomethacinThe American Journal of Medicine, 1986
- DOUBLE-BLIND COMPARISON OF TOLMETIN SODIUM AND INDOMETHACIN IN ANKYLOSING-SPONDYLITIS1982
- Ankylosing Spondylitis: Open Long‐Term and Double‐Blind Crossover Studies with NaproxenThe Journal of Clinical Pharmacology, 1975
- Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis.Annals of the Rheumatic Diseases, 1974